ArticleEuropean journal of nuclear medicine and molecular imaging2008
I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study.
Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 217 citations in OpenAlex.
- Update of the Brazilian Guideline on Nuclear Cardiology - 2020.Arquivos brasileiros de cardiologia · 2020Guideline
- Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology.European journal of nuclear medicine and molecular imaging · 2010Guideline
- Effect of intramyocardial bone marrow-derived mononuclear cell injection on cardiac sympathetic innervation in patients with chronic myocardial ischemia.The international journal of cardiovascular imaging · 2014Trial
- Vascular time-activity variation in patients undergoing ¹²³I-MIBG myocardial scintigraphy: implications for quantification of cardiac and mediastinal uptake.European journal of nuclear medicine and molecular imaging · 2011Trial
- Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine.European journal of nuclear medicine and molecular imaging · 2026Article
- Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial.Cardiovascular diabetology. Endocrinology reports · 2025Article
- The neuronal imaging in cardiology: 123I-Biophysical reviews · 2025Review
- Establishment of aAnnals of nuclear medicine · 2025Article
- The Utility of Baseline Characteristics and [Journal of clinical medicine · 2024Article
- Chagas Cardiomyopathy and Myocardial Sympathetic Denervation.Current cardiology reports · 2024Review
- Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Ischemia and no obstructive coronary arteries (INOCA): A narrative review.Atherosclerosis · 2022Review
- CardiacPharmaceuticals (Basel, Switzerland) · 2022Review
- Prediction of appropriate ICD therapy in patients with ischemic heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Machine learning-based risk model usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction.European journal of nuclear medicine and molecular imaging · 2022Article
- Relationship between heart rate response and cardiac innervation in patients with suspected or known coronary artery disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Comparison between planar and single-photon computed tomography images for radiation intensity quantification in iodine-131 scintigraphy.Scientific reports · 2021Article
- Cardiac Sympathetic Activity and Rhythm Control Following Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation-A ProspectiveJournal of personalized medicine · 2021Article
- How to best appreciate the possible clinical role of cardiacJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSingle-center experiences have shown that myocardial meta-iodobenzylguanidine (mIBG) uptake has prognostic value in heart failure (HF) patients. To verify these observations using a rigorous clinical trial methodology, a retrospective review and prospective quantitative reanalysis was performed on a series of cardiac (123)I-mIBG scans acquired during a 10-year period at six centers in Europe.
methods(123)I-mIBG scans obtained on 290 HF patients [(262 with left ventricular ejection fraction (LVEF) < 50%)] from 1993 to 2002 were reanalyzed using a standardized methodology to determine the heart-to-mediastinum ratio (H/M) on delayed planar images. All image results were verified by three independent reviewers. Major cardiac events [MCEs; cardiac death, cardiac transplant, potentially fatal arrhythmia (including implantable cardioverter-defibrillator discharge)] during 24-month follow-up were confirmed by an adjudication committee.
resultsMCEs occurred in 67 patients (26%): mean H/M ratio was 1.51 +/- 0.30 for the MCE group and 1.97 +/- 0.54 for the non-MCE group (p < 0.001). Two-year event-free survival using an optimum H/M ratio threshold of 1.75 was 62% for H/M ratio less than 1.75, 95% for H/M ratio greater than or equal to 1.75 (p < 0.0001). Logistic regression showed H/M ratio and LVEF as the only significant predictors of MCE. Using the lower and upper H/M quartiles of 1.45 and 2.17 as high- and very low-risk thresholds, 2-year event-free survival rates were 52% and 98%, respectively. Among patients with LVEF < or = 35% and H/M > or = 1.75 (n = 73), there were nine MCEs because of progressive HF and only one because of an arrhythmia.
conclusionApplication of a clinical trial methodology via the retrospective reanalysis of (123)I-mIBG images confirms the previously reported prognostic value of this method in HF patients, including potential identification of a quantitative threshold for low risk for cardiac mortality and potentially fatal ventricular arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.